X

Advanced Search

Select a search constraint:



ArrowEvolution™ with Chlorag<sup>+</sup>ard™ technology

We've rethought the PICC from the inside out.

aiming for zero central-line associated infections

Designed to help clinicians attain and sustain the goal of zero central line–associated bloodstream infections (CLABSIs)

ArrowEVOLUTION with Chlorag+ard technology, the first chlorhexidine-treated peripherally inserted central catheter (PICC) with both intraluminal and extraluminal protection.1

  • Broad-spectrum activity against gram-positive, gram-negative and fungal pathogens, such as MRSA,* VRE,* Staphylococcus epidermidis, Candida albicans and Acinetobacter baumannii1
  • Proven to reduce 99.99% of bacterial and fungal colonization1†
  • Chlorag+ard provides intraluminal and extraluminal protection for at least 30 days1
  • Intraluminal protection plays an important role in reducing microbial colonization, which is a major source of PICC-related infections2

Chlorag+ard technology proven efficacious for at least 1 month1

Chlorhexidine efficacy for at least 30 days

The ArrowEVOLUTION PICC is designed to provide an initial burst of chlorhexidine immediately after insertion to protect the subcutaneous tract. Chlorag+ard continues to release chlorhexidine for at least 30 days, resulting in a 99.99% colonization reduction.1

Instructions for use (PDFPDF 970k)

  • Request more information on ArrowEVOLUTION PICC
  • Watch a video on chlorhexidine in PICCs

*MRSA = methicillin-resistant Staphylococcus aureus; VRE = vancomycin-resistant enterococci.

†Based on in vitro data.

Reference: 1. Data on file, Teleflex Incorporated. 2. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62-67.

Teleflex, ArrowEVOLUTION, Chlorag+ard and ZERO ZONE are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.